Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) continued its monster climb this year with a 10% gain in September, according to data from S&P Global Market Intelligence. Preclinical results presented at a scientific conference boosted the outlook for the company's pulmonary arterial hypertension (PAH) candidate, which recently succeeded in a mid-stage clinical trial.
Arena's lead candidate for the treatment of PAH, ralinepag, hit its primary efficacy endpoint in a 61-patient mid-stage study, but the pulmonary vascular resistance benefit recorded might not be enough to please regulators. The U.S. Food and Drug Administration approved Uptravi, now a Johnson & Johnson drug, in 2015 based on results of a long-term outcome study.
Image source: Getty Images.
Source: Fool.com
